Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600117355) titled 'Efficacy and Safety of Upadacitinib in Active Perianal Fistulizing Crohn's Disease Refractory to Anti-TNF Therapy: A Multicenter, Prospective Observational Study' on Jan. 22.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine
Condition:
Active Perianal Fistulizing Crohn's Disease
Recruitment Status: Recruiting
Phase: 4
Date of First Enrollment: 2025-03-13
Target Sample Size: Active Perianal Fistulizing Crohn's Disease Refractory to Anti-TNF Therapy:90;
Countries of Recruitment:
China
To know more, v...